One systems biology analysis protein-protein interaction of NASH and IBD based on comprehensive gene information

Reza Karbalaei, Mehran Piran, Mostafa Rezaei-Tavirani, Hamid Asadzadeh-Aghdaei, Mohammad Hossein Heidari

Abstract


67

.


Keywords


In?ammatory bowel diseases (IBD), Non-alcoholic steatohepatitis (NASH), Protein-protein interaction (PPI) network analysis, Hub-bottlenecks, Protein clusters

References


Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. Journal of hepatology. 2010;53(2):372-84.

Beaton MD. Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Canadian Journal of Gastroenterology and Hepatology. 2012;26(6):353-7.

Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116(6):1413-9.

McCullough AJ. The epidemiology and risk factors of NASH. Fatty liver disease: NASH and related disorders. 2005:23-37.

Ahmed A, Wong RJ, Harrison SA. Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes. Clinical Gastroenterology and Hepatology. 2015;13(12):2062-70.

Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128(7):1898-906.

Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. Hepatology. 2000;32(3):477-81.

Younossi ZM, McCullough AJ, Ong JP, Barnes DS, Post A, Tavill A, et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. Journal of clinical gastroenterology. 2004;38(8):705-9.

Asadzadeh-Aghdaee H, Shahrokh S, Norouzinia M, Hosseini M, Keramatinia A, Jamalan M, et al. Introduction of inflammatory bowel disease biomarkers panel using protein-protein interaction (PPI) network analysis. Gastroenterology and Hepatology from bed to bench. 2016;9(Suppl1):S8.

Chao C-Y, Battat R, Al Khoury A, Restellini S, Sebastiani G, Bessissow T. Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: a review article. World journal of gastroenterology. 2016;22(34):7727.

Rocchi A, Benchimol EI, Bernstein CN, Bitton A, Feagan B, Panaccione R, et al. Inflammatory bowel disease: a Canadian burden of illness review. Canadian Journal of Gastroenterology and Hepatology. 2012;26(11):811-7.

Steed H, Walsh S, Reynolds N. A brief report of the epidemiology of obesity in the inflammatory bowel disease population of Tayside, Scotland. Obesity facts. 2009;2(6):370-2.

Geerling BJ, Badart-Smook A, Stockbrügger RW, Brummer R. Comprehensive nutritional status in patients with long-standing Crohn disease currently in remission. The American journal of clinical nutrition. 1998;67(5):919-26.

Long MD, Crandall WV, Leibowitz IH, Duffy L, Del Rosario F, Kim SC, et al. Prevalence and epidemiology of overweight and obesity in children with inflammatory bowel disease. Inflammatory bowel diseases. 2011;17(10):2162-8.

Wong RJ, Ahmed A. Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations. World journal of hepatology. 2014;6(5):263.

Gisbert JP, Luna M, González‐Lama Y, Pousa ID, Velasco M, Moreno‐Otero R, et al. Liver injury in inflammatory bowel disease: Long‐term follow‐up study of 786 patients. Inflammatory bowel diseases. 2007;13(9):1106-14.

Sourianarayanane A, Garg G, Smith TH, Butt MI, McCullough AJ, Shen B. Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease☆. Journal of Crohn's and Colitis. 2013;7(8):e279-e85.

Bargiggia S, Maconi G, Elli M, Molteni P, Ardizzone S, Parente F, et al. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. Journal of clinical gastroenterology. 2003;36(5):417-20.

Bessissow T, Le NH, Rollet K, Afif W, Bitton A, Sebastiani G. Incidence and predictors of nonalcoholic fatty liver disease by serum biomarkers in patients with inflammatory bowel disease. Inflammatory bowel diseases. 2016;22(8):1937-44.

Bringiotti R, Ierardi E, Lovero R, Losurdo G, Di Leo A, Principi M. Intestinal microbiota: the explosive mixture at the origin of inflammatory bowel disease? World journal of gastrointestinal pathophysiology. 2014;5(4):550.

Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49(6):1877-87.

Safaei A, Oskouie AA, Mohebbi SR, Rezaei-Tavirani M, Mahboubi M, Peyvandi M, et al. Metabolomic analysis of human cirrhosis, hepatocellular carcinoma, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis diseases. Gastroenterology and hepatology from bed to bench. 2016;9(3):158.

Piñero J, Bravo À, Queralt-Rosinach N, Gutiérrez-Sacristán A, Deu-Pons J, Centeno E, et al. DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants. Nucleic acids research. 2017;45(D1):D833-D9.

Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome research. 2003;13(11):2498-504.

Nepusz T, Yu H, Paccanaro A. Detecting overlapping protein complexes in protein-protein interaction networks. Nature methods. 2012;9(5):471-2.

Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009;25(8):1091-3.

Bindea G, Galon J, Mlecnik B. CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data. Bioinformatics. 2013;29(5):661-3.

Hunter DJ. Gene-environment interactions in human diseases. Nature reviews Genetics. 2005;6(4):287.

Safari-Alighiarloo N, Taghizadeh M, Rezaei-Tavirani M, Goliaei B, Peyvandi AA. Protein-protein interaction networks (PPI) and complex diseases. Gastroenterology and Hepatology from bed to bench. 2014;7(1):17.

Zamanian-Azodi M, Rezaei-Tavirani M, Rahmati-Rad S, Hasanzadeh H, Tavirani MR, Seyyedi SS. Protein-Protein Interaction Network could reveal the relationship between the breast and colon cancer. Gastroenterology and Hepatology from bed to bench. 2015;8(3):215.

Rezaei-Tavirani M, Zamanian-Azodi M, Rajabi S, Masoudi-Nejad A, Rostami-Nejad M, Rahmatirad S. Protein Clustering and Interactome Analysis in Parkinson and Alzheimer's Diseases. Archives of Iranian Medicine (AIM). 2016;19(2).

Safari‐Alighiarloo N, Taghizadeh M, Tabatabaei SM, Shahsavari S, Namaki S, Khodakarim S, et al. Identification of new key genes for type 1 diabetes through construction and analysis of protein–protein interaction networks based on blood and pancreatic islet transcriptomes. Journal of diabetes. 2017;9(8):764-77.

TaviraniPhD MR. Meningioma protein-protein interaction network. Archives of Iranian medicine. 2014;17(4):262.

Abbaszadeh H-A, Peyvandi AA, Sadeghi Y, Safaei A, Zamanian-Azodi M, Khoramgah MS, et al. Er: YAG Laser and Cyclosporin A Effect on Cell Cycle Regulation of Human Gingival Fibroblast Cells. Journal of Lasers in Medical Sciences. 2017;8(3):143-9.

McGowan CE, Jones P, Long MD, Barritt AS. Changing shape of disease: nonalcoholic fatty liver disease in Crohn's disease—a case series and review of the literature. Inflammatory bowel diseases. 2012;18(1):49-54.

Riordan JD, Nadeau JH. Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse. Mammalian genome. 2014;25(9-10):473-86.

Boland BS, Sandborn WJ, Chang JT. Update on Janus kinase antagonists in inflammatory bowel disease. Gastroenterology clinics of North America. 2014;43(3):603-17.

Matthews V, Allen T, Risis S, Chan M, Henstridge D, Watson N, et al. Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia. 2010;53(11):2431-41.

Mudter J, Neurath MF. Il‐6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflammatory bowel diseases. 2007;13(8):1016-23.

Cario E. Toll‐like receptors in inflammatory bowel diseases: a decade later. Inflammatory bowel diseases. 2010;16(9):1583-97.

Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, Rudensky B, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology. 2004;126(2):520-8.

Cengiz M, Ozenirler S, Elbeg S. Role of serum toll‐like receptors 2 and 4 in non‐alcoholic steatohepatitis and liver fibrosis. Journal of gastroenterology and hepatology. 2015;30(7):1190-6.

Farrell GC, Larter CZ, Hou JY, Zhang RH, Yeh MM, Williams J, et al. Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression. Journal of gastroenterology and hepatology. 2009;24(3):443-52.

Goretsky T, Dirisina R, Sinh P, Mittal N, Managlia E, Williams DB, et al. p53 mediates TNF-induced epithelial cell apoptosis in IBD. The American journal of pathology. 2012;181(4):1306-15.




DOI: http://dx.doi.org/10.22037/ghfbb.v0i0.1199

Creative Commons License
GHFBB by Gastroenterology and Liver Diseases Research Institute is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

PISSN: 2008-2258

EISSN: 2008-4234


•  

Privacy Policy | For Author | Online Submission | About | Contact

Copyright © 2016 Shahid Beheshti University of Medical Sciences. All rights reserved.